188.8.131.52 Somatostatin analogues
Treatment should only be initiated on the advice of a hospital specialist.
Lanreotide (injection), octreotide (injection) pasireotide (injection) are analogues of the hypothalamic release-inhibiting hormone somatostatin. They are indicated for the relief of symptoms associated with neuroendocrine (particularily carcinoid) tumours and acromegaly. Lanreotide is also licensed for the treatment of thyroid tumours and octreotide is licensed for the prevention of complications following pancreatic surgery.
Pasireotide (as pamoate) 20mg, 40mg, 60mg powder and solvent for suspension for injection (Signifor®) is available for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue as per SMC 1048/15. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting. Treatment is initiated in hospital prior to handover. Managed transfer to Primary Care is on an individual basis subject to provision of an individual care plan and training Primary Care healthcare staff on the correct reconstitution of pasireotide pamoate (Signifor®) , see SmPC.